Liqiong Xue

1800 Yun Tai Road
Shanghai, 200123, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials.

FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials.

Journal: Targeted oncology

Published: June 16, 2026

Molecular Subtype-Associated Response to Cyclophosphamide-Epirubicin-Cisplatin Regimen in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Retrospective Single-Center Study.

Molecular Subtype-Associated Response to Cyclophosphamide-Epirubicin-Cisplatin Regimen in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Retrospective Single-Center Study.

Journal: Cancers

Published: May 11, 2026

Efficacy of first-line immune checkpoint inhibitors for recurrent/metastatic head and neck cancer: a systematic review and meta-analysis.

Efficacy of first-line immune checkpoint inhibitors for recurrent/metastatic head and neck cancer: a systematic review and meta-analysis.

Journal: Immunotherapy

Published: April 14, 2026

Safety, pharmacokinetics, pharmacodynamics and antitumor activity of legubicin in patients with advanced solid tumors, including lung cancer: a phase 1 dose-escalation and expansion trial.

Safety, pharmacokinetics, pharmacodynamics and antitumor activity of legubicin in patients with advanced solid tumors, including lung cancer: a phase 1 dose-escalation and expansion trial.

Journal: BMC cancer

Published: April 12, 2026

Intravenous amivantamab after cetuximab failure in recurrent or metastatic head and neck squamous cell carcinoma: a single-centre retrospective real-world cohort study.

Intravenous amivantamab after cetuximab failure in recurrent or metastatic head and neck squamous cell carcinoma: a single-centre retrospective real-world cohort study.

Journal: Oral oncology

Published: April 06, 2026

Therapeutic targeting of toll-like receptor pathways in tumor-associated macrophages.

Therapeutic targeting of toll-like receptor pathways in tumor-associated macrophages.

Journal: Cytokine & growth factor reviews

Published: January 09, 2026

Epigenetic silencing of GPD1 by HDAC2 via H3K9 deacetylation promotes head and neck squamous cell carcinoma progression.

Epigenetic silencing of GPD1 by HDAC2 via H3K9 deacetylation promotes head and neck squamous cell carcinoma progression.

Journal: Experimental cell research

Published: October 24, 2025

Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial.

Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 16, 2025

Artemisinin sensitizes triple negative breast cancer to immune checkpoint therapy through suppressing KEAP1-mediated PD-L1 degradation.

Artemisinin sensitizes triple negative breast cancer to immune checkpoint therapy through suppressing KEAP1-mediated PD-L1 degradation.

Journal: Biochemical pharmacology

Published: October 10, 2025

Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma.

Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma.

Journal: Cancer treatment reviews

Published: September 08, 2025

Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 study.

Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 study.

Journal: Signal transduction and targeted therapy

Published: June 20, 2025

Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors.

Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors.

Journal: Frontiers in oncology

Published: August 11, 2023

Showing 1-12 of 24

Last Updated: 09/26/2026